FDA Reassures Patients Of Generic Drug Quality Amid Questions In Media Analysis
Executive Summary
Commissioner Scott Gottlieb and CDER Director Janet Woodcock say in joint statement that patients can be confident generics are safe and effective and recent media reports misinterpreted inspection and other data when suggesting the contrary.
You may also be interested in...
House Committee Wants Answers On Foreign Inspections And Valsartan Crisis
A bipartisan group of lawmakers is concerned about the growing number of recalls of blood pressure medicines from foreign manufacturing sites in China and India and wants answers from GAO and FDA.
US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes
Legislative proposal in FY 2020 budget request wouldn't necessarily reduce number of complete response letters, but ability to require reports and postmarket changes on quality issues might eventually create more flexibility during initial product reviews.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.